Trial Profile
A Phase I Dose Escalation Study to Investigate the Safety, Tolerability, and Pharmacokinetics of SHC014748M in Patients With Relapsed or Refractory Indolent B-Cell Hematologic Malignancies.
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 05 Apr 2021
Price :
$35
*
At a glance
- Drugs SHC-014748M (Primary)
- Indications B-cell leukaemia; B-cell lymphoma; Chronic lymphocytic leukaemia; Follicular lymphoma; Haematological malignancies; Marginal zone B-cell lymphoma; Waldenstrom's macroglobulinaemia
- Focus Adverse reactions; First in man; Pharmacokinetics
- Sponsors Nanjing Sanhome Pharmaceutical
- 06 Nov 2019 Interim results (n=38) released at the 61st Annual Meeting and Exposition of the American Society of Hematology
- 23 Jul 2018 New trial record